Sun Pharma and Philogen enter into exclusive agreement for commercialising skin cancer drug in Europe, Australia and New Zealand
Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand.